Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 113

Results For "cancer"

1257 News Found

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies
interviews | February 15, 2022

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies

BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post

Gamida Cell initiates rolling submission of Biologics License Application for Omidubicel
Biotech | February 10, 2022

Gamida Cell initiates rolling submission of Biologics License Application for Omidubicel

On track to complete the BLA submission in the first half of 2022

EdiGene and Neukio collaborate to develop next-generation immune cell therapies
Biotech | February 09, 2022

EdiGene and Neukio collaborate to develop next-generation immune cell therapies

The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)

Strand Therapeutics appoints Dr. Prashant Nambiar as Senior VP
People | February 09, 2022

Strand Therapeutics appoints Dr. Prashant Nambiar as Senior VP

Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics

Alkem enters exclusive license agreement with Johns Hopkins University
Healthcare | January 31, 2022

Alkem enters exclusive license agreement with Johns Hopkins University

The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer

Lonza partners with biotech firm HaemaLogiX on multiple myeloma drug candidate
Biotech | January 29, 2022

Lonza partners with biotech firm HaemaLogiX on multiple myeloma drug candidate

Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China

European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC
Drug Approval | January 28, 2022

European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC

KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)

Sanofi signs as first partner of Protas
Biotech | January 25, 2022

Sanofi signs as first partner of Protas

The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases

Advent to acquire controlling stake in Avra Labs
News | January 24, 2022

Advent to acquire controlling stake in Avra Labs

Avra Labs is a Hyderabad based contract manufacturing and research services (CRAMs) and specialty active pharmaceutical ingredients (API) manufacturer with four facilities across the states of Telangana and Andhra Pradesh

Bristol Myers Squibb receives approval for Abecma in Japan
Drug Approval | January 21, 2022

Bristol Myers Squibb receives approval for Abecma in Japan

It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan

Latest Stories

FDA nod to first oral single-dose treatment for gonorrhea

ImmunityBio’s ANKTIVA wins EMA nod for early EU approval in hard-to-treat bladder cancer

Accenture invests in Ryght AI to revolutionize clinical trials

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories
Companies must shift from L1 costing to Life Cycle Cost Analysis: Abhilash Pasham, Associate GM - Central Engineering & Projects, Dr. Reddy's Laboratories

Packaging